CR7171A - Composiciones farmaceuticas de farmacos y polimeros acidos neutralizados - Google Patents

Composiciones farmaceuticas de farmacos y polimeros acidos neutralizados

Info

Publication number
CR7171A
CR7171A CR7171A CR7171A CR7171A CR 7171 A CR7171 A CR 7171A CR 7171 A CR7171 A CR 7171A CR 7171 A CR7171 A CR 7171A CR 7171 A CR7171 A CR 7171A
Authority
CR
Costa Rica
Prior art keywords
pharmaceutical compositions
polymers
pharmaces
neutralized acid
acid
Prior art date
Application number
CR7171A
Other languages
English (en)
Inventor
Blair West James
David Crew Marshall
Thomas Friesen Dwayne
James Ketner Rodney
Mysore Shanker Ravi
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of CR7171A publication Critical patent/CR7171A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/717—Celluloses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polymerisation Methods In General (AREA)
  • Quinoline Compounds (AREA)

Abstract

Se describen composiciones farmaceuticas que comprenden farmacos de solubilidad baja y/o sensibles a acidos, y polimeros acidos neutralizados
CR7171A 2001-06-22 2003-11-27 Composiciones farmaceuticas de farmacos y polimeros acidos neutralizados CR7171A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30025601P 2001-06-22 2001-06-22

Publications (1)

Publication Number Publication Date
CR7171A true CR7171A (es) 2004-02-23

Family

ID=23158332

Family Applications (1)

Application Number Title Priority Date Filing Date
CR7171A CR7171A (es) 2001-06-22 2003-11-27 Composiciones farmaceuticas de farmacos y polimeros acidos neutralizados

Country Status (28)

Country Link
US (3) US20030054038A1 (es)
EP (1) EP1399190B1 (es)
JP (1) JP2004534822A (es)
KR (1) KR20040011549A (es)
CN (1) CN1545421A (es)
AT (1) ATE480226T1 (es)
BG (1) BG108488A (es)
BR (1) BR0210530A (es)
CA (1) CA2450762A1 (es)
CO (1) CO5540325A2 (es)
CR (1) CR7171A (es)
CZ (1) CZ20033457A3 (es)
DE (1) DE60237602D1 (es)
EA (1) EA200301250A1 (es)
EC (1) ECSP034913A (es)
EE (1) EE200400033A (es)
HU (1) HUP0400264A2 (es)
IL (1) IL158991A0 (es)
IS (1) IS7047A (es)
MA (1) MA27039A1 (es)
MX (1) MXPA03011933A (es)
NO (1) NO20035699D0 (es)
OA (1) OA12624A (es)
PL (1) PL368587A1 (es)
SK (1) SK15732003A3 (es)
TN (1) TNSN03137A1 (es)
WO (1) WO2003000292A1 (es)
ZA (1) ZA200308989B (es)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5767429B2 (ja) * 1999-11-12 2015-08-19 アッヴィ・インコーポレイテッド 固体分散剤中の結晶化阻害剤
US7364752B1 (en) 1999-11-12 2008-04-29 Abbott Laboratories Solid dispersion pharamaceutical formulations
DE10026698A1 (de) * 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
US7115279B2 (en) 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
EP1308228B1 (en) * 2000-08-11 2007-06-13 Ishihara Sangyo Kaisha, Ltd. Colloidal metal solution, process for producing the same, and coating material containing the same
US20050260273A1 (en) * 2001-06-07 2005-11-24 Chinea Vanessa I Applicatin of a bioactive agent in a solvent composition to produce a target particle morphology
BR0210518A (pt) * 2001-06-22 2004-06-22 Pfizer Prod Inc Composições farmacêuticas de dispersões de drogas e polìmeros neutros
EP1269994A3 (en) * 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
AR038375A1 (es) 2002-02-01 2005-01-12 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
DE60331873D1 (de) * 2002-12-20 2010-05-06 Pfizer Prod Inc Dosierungsform enthaltend einen CETP-Hemmer und einen HMG-CoA Reduktase Hemmer
US20070059346A1 (en) * 2003-07-01 2007-03-15 Todd Maibach Film comprising therapeutic agents
CN100508976C (zh) * 2003-07-24 2009-07-08 史密丝克莱恩比彻姆公司 口腔溶解薄膜
US7838029B1 (en) * 2003-07-31 2010-11-23 Watson Laboratories, Inc. Mirtazapine solid dosage forms
WO2005011634A1 (en) * 2003-08-04 2005-02-10 Pfizer Products Inc. Dosage forms providing controlled release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
ATE409462T1 (de) * 2004-05-28 2008-10-15 Pfizer Prod Inc Pharmazeutische zusammensetzungen mit verbesserter leistung enthaltend ein hpmca polymer
WO2006064906A1 (ja) * 2004-12-17 2006-06-22 Ono Pharmaceutical Co., Ltd. 非晶質性組成物
EP1844078B1 (en) * 2005-02-03 2016-09-28 Bend Research, Inc Pharmaceutical compositions with enhanced performance
DE102005007059A1 (de) * 2005-02-15 2006-08-24 Röhm GmbH & Co. KG Teilneutralisiertes anionisches (Meth)acrylat-Copolymer
US20060228487A1 (en) * 2005-04-11 2006-10-12 J. Rettenmaier & Söehne GmbH + Co. KG Methods of combining active agents with augmented microcrystalline cellulose
US8093408B2 (en) * 2005-06-21 2012-01-10 The Company Wockhardt Antidepressant oral pharmaceutical compositions
US8153824B2 (en) * 2005-06-22 2012-04-10 The Wockhardt Company Antidepressant oral liquid compositions
US20060165776A1 (en) * 2005-08-31 2006-07-27 Ramesh Sesha Antidepressant oral pharmaceutical compositions
US7811604B1 (en) 2005-11-14 2010-10-12 Barr Laboratories, Inc. Non-effervescent, orally disintegrating solid pharmaceutical dosage forms comprising clozapine and methods of making and using the same
GB0613925D0 (en) * 2006-07-13 2006-08-23 Unilever Plc Improvements relating to nanodispersions
US8372836B2 (en) * 2006-10-17 2013-02-12 Bend Research, Inc. Spray dried formulation
PE20081506A1 (es) * 2006-12-12 2008-12-09 Infinity Discovery Inc Formulaciones de ansamicina
WO2008098195A2 (en) * 2007-02-09 2008-08-14 Todd Maibach Film comprising nitroglycerin
GB2446953A (en) * 2007-02-24 2008-08-27 Agt Sciences Ltd Aqueous pharmaceutical formulations
GB0703627D0 (en) * 2007-02-24 2007-04-04 Agt Sciences Ltd Aqueous formulations
SI2152250T1 (sl) * 2007-05-07 2020-06-30 Evonik Operations Gmbh Trdne dozirne oblike, ki vsebujejo enterično oplaščenje s pospešenim sproščanjem zdravila
WO2009022821A2 (en) * 2007-08-13 2009-02-19 Hanall Pharmaceutical Company. Ltd Combination preparation comprising inhibitor of hmg-coa reductase and aspirin and method for manufacturing the same
EP2240162A4 (en) * 2007-12-06 2013-10-09 Bend Res Inc NANOTE PARTICLES WITH A NON-IONIZABLE POLYMER AND AN AMIN-FUNCTIONALIZED METHACRYLATE COPOLYMER
JP5646340B2 (ja) * 2007-12-12 2014-12-24 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ ポリマー性対イオンと活性成分との塩
US20100184870A1 (en) * 2008-03-14 2010-07-22 Rolf Groteluschen Long-term stable pharmaceutical preparation containing the active ingredient glycerol trinitrate
WO2009136398A2 (en) * 2008-05-06 2009-11-12 Dexcel Ltd Stable benzimidazole formulation
ES2550942T3 (es) 2009-12-03 2015-11-13 Alcon Research, Ltd. Suspensiones de nanopartículas que contienen polímero de carboxivinilo
AU2011287948B2 (en) 2010-08-03 2014-11-06 G. Pohl-Boskamp Gmbh & Co. Kg Use of glyceryl trinitrate for treating traumatic edema
EP2678006B1 (en) 2011-02-25 2015-12-30 G. Pohl-Boskamp GmbH & Co. KG Packaging of solid pharmaceutical preparations containing the active substance glyceryl trinitrate
US20130338121A1 (en) * 2011-03-01 2013-12-19 Le Tien Canh Two speed monolithic system for controlled release of drugs
IN2014CN00827A (es) * 2011-08-16 2015-04-03 Merck Sharp & Dohme
US9248099B2 (en) 2012-05-31 2016-02-02 Desmoid Aktiengesellschaft Use of stabilized granules containing glyceryl trinitrate for arteriogenesis
HUE033092T2 (hu) 2012-05-31 2017-11-28 G Pohl-Boskamp Gmbh & Co Kg Arteriogenezis indukálása nitroglicerinnel mint nitrogén-oxid donorral
CA2904052A1 (en) * 2013-03-14 2014-10-02 Shire Human Genetic Therapies, Inc. Methods of treating b2-bradykinin receptor mediated angioedema
EP2878310B1 (en) 2013-11-29 2017-01-11 G. Pohl-Boskamp GmbH & Co. KG Sprayable aqueous composition comprising glyceryl trinitrate
CN106232144B (zh) * 2014-03-18 2019-12-06 武田药品工业株式会社 固体分散体
EP3226843B1 (en) 2014-12-05 2021-05-26 Aragon Pharmaceuticals, Inc. Anticancer compositions
MA41107A (fr) * 2014-12-05 2017-10-10 Aragon Pharmaceuticals Inc Compositions anti-cancéreuses
KR20190022640A (ko) * 2016-06-23 2019-03-06 다우 글로벌 테크놀로지스 엘엘씨 프탈릴기를 포함하는 에스터화된 셀룰로스 에터
KR20190042604A (ko) * 2016-08-23 2019-04-24 다우 글로벌 테크놀로지스 엘엘씨 셀룰로스 에테르 아세테이트 프탈레이트
CN110225877B (zh) * 2016-12-21 2022-01-25 可口可乐公司 分配低溶解度配料的饮料分配器
US10347667B2 (en) * 2017-07-26 2019-07-09 International Business Machines Corporation Thin-film negative differential resistance and neuronal circuit
ES2967689T3 (es) 2018-04-06 2024-05-03 Capsugel Belgium Nv Proceso de secado por aspersión para partículas de baja relación de aspecto que comprenden poli[(metacrilato de metilo)-co-(ácido metacrílico)]
CA3107665A1 (en) 2018-07-30 2020-02-06 Chugai Seiyaku Kabushiki Kaisha Solid dispersion of hydantoin derivative
WO2021028832A1 (en) * 2019-08-15 2021-02-18 Capsugel Belgium Nv Ammonia as a processing aid for sprayed solid dispersions
CN111973596B (zh) * 2020-06-15 2022-02-15 深圳市泰力生物医药有限公司 具有改良溶出性质的抗肺纤维化组合物
WO2023086832A1 (en) * 2021-11-09 2023-05-19 Board Of Regents, The University Oftexas System Methods of preparing dosage forms using 3d printing containing amorphous solid dispersions

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2830987A (en) * 1958-04-15 Derivatives of phenthiazine
US565629A (en) * 1896-08-11 Fastener for bottles
US103225A (en) * 1870-05-17 andrew myers
US522520A (en) * 1894-07-03 Flower-holder for florists use
US2784185A (en) * 1953-03-27 1957-03-05 Promonta Chem Fab Phenothiazine compounds
US2901478A (en) * 1957-02-11 1959-08-25 Promonta Chem Fab Phenothiazine compounds
DE3013839A1 (de) * 1979-04-13 1980-10-30 Freunt Ind Co Ltd Verfahren zur herstellung einer aktivierten pharmazeutischen zusammensetzung
US4689319A (en) * 1983-01-13 1987-08-25 Colorado State University Research Foundation Oral energy rich therapy for diarrhea in mammals
JPS59193832A (ja) 1983-04-18 1984-11-02 Sankyo Co Ltd 腸溶性製剤の製法
DE3438830A1 (de) * 1984-10-23 1986-04-30 Rentschler Arzneimittel Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung
US4753800A (en) * 1985-10-04 1988-06-28 Warner-Lambert Company Medicament adsorbates and their preparation
IE63321B1 (en) 1986-02-03 1995-04-05 Elan Corp Plc Drug delivery system
US4867970A (en) 1987-05-21 1989-09-19 E. R. Squibb & Sons, Inc. Moistureless oral drug delivery formulation and method for preparing same
US4835186A (en) 1987-06-15 1989-05-30 American Home Products Corporation Spray dried ibuprofen
FR2632521B1 (fr) * 1988-06-10 1990-09-14 Rhone Poulenc Sante Nouveaux derives de la phenothiazine, leur preparation et les compositions pharmaceutiques qui les contiennent
JP2893191B2 (ja) * 1988-11-08 1999-05-17 武田薬品工業株式会社 放出制御性マトリックス剤
EP0462066A1 (en) 1990-06-15 1991-12-18 Warner-Lambert Company Amorphous gemfibrozil
AU1537292A (en) 1991-04-16 1992-11-17 Nippon Shinyaku Co. Ltd. Method of manufacturing solid dispersion
US5225202A (en) * 1991-09-30 1993-07-06 E. R. Squibb & Sons, Inc. Enteric coated pharmaceutical compositions
JP3142919B2 (ja) * 1991-11-06 2001-03-07 旭化成株式会社 セルロース誘導体ラテックス及びその製法
DE69222182T2 (de) 1991-12-18 1998-02-26 Warner Lambert Co Verfahren für die herstellung einer festen dispersion
US5656297A (en) 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
DE4316537A1 (de) * 1993-05-18 1994-11-24 Basf Ag Zubereitungen in Form fester Lösungen
US5508276A (en) * 1994-07-18 1996-04-16 Eli Lilly And Company Duloxetine enteric pellets
NZ280610A (en) * 1994-12-29 1997-08-22 Mcneil Ppc Inc Soft gelatin-like pharmaceutical carrier: gelled polyethylene glycol and dispersed active agent
US5945124A (en) * 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole
DE19637517A1 (de) * 1996-09-13 1998-03-19 Basf Ag Herstellung von pulverförmigen, kaltwasserdispergierbaren Carotinoid-Zubereitungen und die Verwendung der neuen Carotinoid-Zubereitungen
US6306434B1 (en) * 1997-02-12 2001-10-23 Chong Kun Dang Corp. Pharmaceutical composition comprising cyclosporin solid-state microemulsion
US5955475A (en) * 1997-06-30 1999-09-21 Endo Pharmaceuticals Inc. Process for manufacturing paroxetine solid dispersions
EP0901786B1 (en) * 1997-08-11 2007-06-13 Pfizer Products Inc. Solid pharmaceutical dispersions with enhanced bioavailability
US6350786B1 (en) 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
ATE400252T1 (de) * 1999-02-10 2008-07-15 Pfizer Prod Inc Pharmazeutische feste dispersionen
DE60042352D1 (de) 1999-02-10 2009-07-23 Pfizer Prod Inc Osmotisches System zur Verabreichung von Wirkstoffen, die feste amorphe Dispersionen enthalten
US6706283B1 (en) * 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
EP1027887B1 (en) 1999-02-10 2008-08-13 Pfizer Products Inc. Matrix controlled release device
DE19918434A1 (de) * 1999-04-23 2000-10-26 Basf Ag Feste Pharmazeutische Formulierungen von säurelabilen Protonenpumpenblockern
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
EP1686120A3 (en) 1999-10-27 2007-05-30 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US6468559B1 (en) * 2000-04-28 2002-10-22 Lipocine, Inc. Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods
US7115279B2 (en) * 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
EP1360180A1 (en) 2001-01-19 2003-11-12 Cytokinetics, Inc. Phenothiazine kinesin inhibitors

Also Published As

Publication number Publication date
SK15732003A3 (sk) 2005-01-03
TNSN03137A1 (en) 2005-12-23
ECSP034913A (es) 2004-01-28
ATE480226T1 (de) 2010-09-15
OA12624A (en) 2006-06-12
US20060003011A1 (en) 2006-01-05
WO2003000292A1 (en) 2003-01-03
EE200400033A (et) 2004-06-15
US8173142B2 (en) 2012-05-08
HUP0400264A2 (hu) 2004-08-30
MA27039A1 (fr) 2004-12-20
US8147872B2 (en) 2012-04-03
CO5540325A2 (es) 2005-07-29
EA200301250A1 (ru) 2004-06-24
CA2450762A1 (en) 2003-01-03
IS7047A (is) 2003-11-20
CN1545421A (zh) 2004-11-10
IL158991A0 (en) 2004-05-12
ZA200308989B (en) 2004-11-19
EP1399190A1 (en) 2004-03-24
MXPA03011933A (es) 2004-03-26
BG108488A (bg) 2005-01-31
NO20035699D0 (no) 2003-12-19
CZ20033457A3 (cs) 2004-09-15
KR20040011549A (ko) 2004-02-05
BR0210530A (pt) 2004-06-22
PL368587A1 (en) 2005-04-04
EP1399190B1 (en) 2010-09-08
US20060204577A1 (en) 2006-09-14
JP2004534822A (ja) 2004-11-18
US20030054038A1 (en) 2003-03-20
DE60237602D1 (de) 2010-10-21

Similar Documents

Publication Publication Date Title
CR7171A (es) Composiciones farmaceuticas de farmacos y polimeros acidos neutralizados
HN2002000152A (es) Composiciones farmaceuticas que contienen conjuntos de polimero y farmaco
HN2001000244A (es) Inhibidores de espiropirimidin - 2, 4, 6 - triona metaloproteinasas.
HN2002000247A (es) Derivados de sulfonamida
NO20074807L (no) Fast farmasoytisk doseringsformulering
BRPI0418330A (pt) composições sólidas de drogas de solubilidade baixa e poloxámeros
PA8506101A1 (es) Uso de un compuesto acat para fabricar una composicion farmaceutica
CY1110906T1 (el) Φαρμακευτικη συνθεση για ρινικη χορηγηση φεντανυλης
SE0101932D0 (sv) Pharmaceutical combinations
HN2002000300A (es) Nuevos derivados de piperazina
HN2002000332A (es) Sales de acido succinico de 5,7,14 triazatetraciclo (10. 3.1.02.11.04,9)-hexadeca-2 (11), 3,5,7,9-pentaeno y composiciones farmaceuticas de las mismas
UY27929A1 (es) Composiciones farmaceuticas de farmacos semiordenados y polimeros
DOP2000000022A (es) Combinacion de inhibidores de mtp e inhibidores de hmg-coa reductasa y su uso en medicametos.
ES2422081T3 (es) Péptido Ser-Ser-Ser-Arg y sus utilizaciones medicinales
BRPI0408299A (pt) inibidores de catepsina s
DK1537065T3 (da) Analoger af D-vitamin
DK1558219T3 (da) Farmaceutisk formulering af olanzapin
TR200302134T4 (tr) 2-metil-tiazolidin-2,4-dikarboksilik asit ve/veya bunun fizyolojik olarak uygun tuzlarının anti-kanser ajanları olarak kullanımı.
ATE297760T1 (de) Pharmazeutische zusammensetzungen enthaltend terbinafin
BR0206960A (pt) Composição farmacêutica oral, e, uso de um polìmero de ftalato de hidroxipropilmetilcelulose
HRPK20030766B3 (en) Combination of a taxane and cyclin-dependent kinase inhibitor
PT1411956E (pt) Utilizacao de polissacaridos sobre-sulfatados como inibidores de vih
CY1106129T1 (el) Κιταλοπραμη για την αγωγη της υψηλης πιεσεως του αιματος
DOP2002000421A (es) Composiciones farmaceuticas que contienen conjunto de pollimero y farmaco.
UA38889A (uk) Лікувальний засіб "ліварекс" на основі диметоксіуреїдофосфорної кислоти

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)